We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
Read MoreHide Full Article
ABIOMED, Inc. is scheduled to release first-quarter fiscal 2020 results on Aug 1, before market opens. We believe that despite persistent foreign currency woes, solid prospects of the flagship Impella product line will reflect on the results.
ABIOMED’s last-quarter earnings were in line with estimates, with the average earnings surprise being a positive 2.9% for the trailing four quarters.
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for ABIOMED’s fiscal first-quarter earnings is pegged at 99 cents, indicating year-over-year improvement of 26.9%. The same for revenues stands at $210.6 million, suggesting an increase of 17% year over year.
Let’s see how things are shaping up prior to the earnings release.
Impella Likely to Drive Q1 Results
ABIOMED’s flagship product line, Impella, has consistently provided a boost to the top line. Impella, a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart, is expected to have driven first-quarter results.
ABIOMED’s progress with respect to SmartAssist, Impella Connect, IQ Impella Quality Assurance Database, Impella RP and Impella 5.0 are expected to show on first-quarter results. The flagship platform also received a series of regulatory approvals recently.
It is encouraging to note that, in May, the company’s Impella 5.0 and Impella LD received FDA approval for treating cardiogenic shock. Other versions like Impella 2.5 and Impella CP have also been approved by the FDA to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions.
Also, at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions, ABIOMED announced the commercial availability of Impella CP with SmartAssist. (Read More: ABIOMED to Launch Impella CP With SmartAssist at SCAI)
Moreover, FDA recently validated the company’s Impella RP heart pump to be safe and effective for treatment of right heart failure. Hence, Impella now ensures higher survival and native heart recovery. Such positive trends are expected to have significantly boosted the results for the quarter-to-be-reported.
Other Factors at Play
ABIOMED issued an impressive view for fiscal 2020.
Notably, the company expects total revenues within $900 million to $945 million, suggesting an increase of 17-23% from fiscal 2019.
This is also indicative of strong top-line performance for the quarter to be reported.
However, headwinds like fluctuation in currency exchange rates might are likely to have affected international sales. ABIOMED has businesses across Europe and earns primarily in Euro and British pound. Due to a sluggish European economy, international revenues are likely to have been affected in the to-be-reported quarter.
Also, ABIOMED faces tough competition in the cardiac devices space, which might weigh on margins.
What Does Our Model Say?
Our proven model says that a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to deliver a positive earnings surprise. However, that is not the case here.
Earnings ESP: ABIOMED has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +6.95% and a Zacks Rank #1.
Allena Pharmaceuticals, Inc. has an Earnings ESP of +7.55% and a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
ABIOMED, Inc. is scheduled to release first-quarter fiscal 2020 results on Aug 1, before market opens. We believe that despite persistent foreign currency woes, solid prospects of the flagship Impella product line will reflect on the results.
ABIOMED’s last-quarter earnings were in line with estimates, with the average earnings surprise being a positive 2.9% for the trailing four quarters.
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for ABIOMED’s fiscal first-quarter earnings is pegged at 99 cents, indicating year-over-year improvement of 26.9%. The same for revenues stands at $210.6 million, suggesting an increase of 17% year over year.
ABIOMED, Inc. Price and EPS Surprise
ABIOMED, Inc. price-eps-surprise | ABIOMED, Inc. Quote
Let’s see how things are shaping up prior to the earnings release.
Impella Likely to Drive Q1 Results
ABIOMED’s flagship product line, Impella, has consistently provided a boost to the top line. Impella, a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart, is expected to have driven first-quarter results.
ABIOMED’s progress with respect to SmartAssist, Impella Connect, IQ Impella Quality Assurance Database, Impella RP and Impella 5.0 are expected to show on first-quarter results. The flagship platform also received a series of regulatory approvals recently.
It is encouraging to note that, in May, the company’s Impella 5.0 and Impella LD received FDA approval for treating cardiogenic shock. Other versions like Impella 2.5 and Impella CP have also been approved by the FDA to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions.
Also, at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions, ABIOMED announced the commercial availability of Impella CP with SmartAssist. (Read More: ABIOMED to Launch Impella CP With SmartAssist at SCAI)
Moreover, FDA recently validated the company’s Impella RP heart pump to be safe and effective for treatment of right heart failure.
Hence, Impella now ensures higher survival and native heart recovery. Such positive trends are expected to have significantly boosted the results for the quarter-to-be-reported.
Other Factors at Play
ABIOMED issued an impressive view for fiscal 2020.
Notably, the company expects total revenues within $900 million to $945 million, suggesting an increase of 17-23% from fiscal 2019.
This is also indicative of strong top-line performance for the quarter to be reported.
However, headwinds like fluctuation in currency exchange rates might are likely to have affected international sales. ABIOMED has businesses across Europe and earns primarily in Euro and British pound. Due to a sluggish European economy, international revenues are likely to have been affected in the to-be-reported quarter.
Also, ABIOMED faces tough competition in the cardiac devices space, which might weigh on margins.
What Does Our Model Say?
Our proven model says that a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to deliver a positive earnings surprise. However, that is not the case here.
Earnings ESP: ABIOMED has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Adamis Pharmaceuticals Corporation has an Earnings ESP of +11.76% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +6.95% and a Zacks Rank #1.
Allena Pharmaceuticals, Inc. has an Earnings ESP of +7.55% and a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>